Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2022

Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation

Published 8 April 2022
Categorized as 2022, Myvac, Publication, TG4050

Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050

Transgene to present new positive preliminary Phase I Clinical data

Published 8 April 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Availability of Transgene’s 2021 Universal Registration Document

Availability of Transgene’s universal registration document

Published 7 April 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022

Availability of Preparatory documents

Published 5 April 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman

Transgene’s board of directors strengthens its governance

Published 31 March 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022

Transgene confirms the potential of its two innovative platforms

Published 16 March 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

Transgene to present new positive preliminary Phase I data on TG4050

Published 9 March 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022

Transgene and BioInvent Announce Poster Presentation on BT-001

Published 9 March 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Press release

Transgene appoints Steven Bloom as Chief Business Officer

Transgene appoints Steven Bloom as Chief Business Officer

Published 10 February 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade

Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade

Published 20 January 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu